If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $CMLS III / $EQRX how you can actually recover something: https://11th.com/cases/cmlsiii-investor-settlement
$EQRX / $CMLS III $7.25 million investor settlement: deadline passed but late claims ARE still open
If you held CMLS III Class A shares between December 14, 2021 and December 17, 2021, you may be eligible, even though the original deadline has passed.
What happened?
Investors alleged that CMLS III made misleading statements about its merger with Legacy EQRx that discouraged shareholders from exercising their redemption rights. After the merger closed, many investors who stayed invested experienced significant losses.
Investors sued, and a $7.25 million settlement was finalized in January 2026.
File your claim: https://11th.com/cases/cmlsiii-investor-settlement
Remember when CM Life Sciences III ($CMLT) merged with EQRx ($EQRX)?
After the deal closed, some investors claimed the merger process wasn't handled fairly and that shareholders were not given all the information they should have received. The dispute eventually led to a $7.25 million settlement
If you held $CMLT shares between December 14, 2021 and December 17, 2021 redemption deadline, you may be eligible for part of the recovery.
The original claim deadline has passed, but late claims are still being reviewed.
If you owned $CMLT during the merger, it may be worth checking whether you can still file a late claim. https://11th.com/cases/cmlsiii-investor-settlement
With everything going on around CMLS III now $EQRX
lately — this is the info you don’t want to miss, late claims are being accepted: https://11th.com/cases/cmlsiii-investor-settlement
The $7,25 million CM Life Sciences III (CMLS III) now EQRx ($EQRX) deadline is this week (May 24, 2026)
If you bought shares between December 14, 2021 and December 17, 2021, you are likely eligible for the $7,25 million recovery fund.
This settlement resolves claims that EQRx misled investors regarding its merger and the value of their redemption rights. The stock dropped following the disclosure, and now the company is paying back to impacted shareholders.
File your claim here: https://11th.com/cases/cmlsiii-investor-settlement
The $7.25 million CM Life Sciences III (CMLS III) now EQRx ($EQRX) deadline is May 24, 2026
If you bought shares between December 14, 2021 and December 17, 2021, you are likely eligible for the $7.25 million recovery fund.
This settlement resolves claims that EQRx misled investors regarding misleading investors about its merger and the value of their redemption rights. The stock dropped following the disclosure, and now the company is paying back to impacted shareholders.
File your claim here: https://11th.com/cases/cmlsiii-investor-settlement
Don't forget that there is also an important settlement to watch for $EQRX.
We have every detail, including how investors can get paid. The deadline to submit a claim is May 24, 2026: https://11th.com/cases/cmlsiii-investor-settlement
$EQRX investors — there's no hidden secret here. Just one thing you really need to know.
Here's how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/cmlsiii-investor-settlement
When we see a stock like this, we know how many damaged investors are out there.
Believe it or not, there's some good news.
$EQRX investors — you might be surprised, but you actually have a chance to recover your losses. Don't miss it: https://11th.com/cases/cmlsiii-investor-settlement
Don't miss this update. This is probably the most useful info you've read in years about $EQRX — how you can actually recover something: https://11th.com/cases/cmlsiii-investor-settlement
$EQRX has reached a $7,250,000 settlement with former CMLS III Class A stockholders over claims that their redemption rights were impaired in connection with the CMLS III–Legacy EQRx merger.
The filing deadline is May 24, 2026. If you held CMLS III Class A shares between December 14, 2021 and December 17, 2021, you can file for payment here: https://11th.com/cases/cmlsiii-investor-settlement
$EQRX has reached a $7,25M settlement with $EQRX investors over claims that former CMLS III Class A stockholders’ redemption rights were allegedly impaired in connection with the CMLS III–Legacy EQRx merger.
The filing deadline is May 24, 2026. If you held CMLS III Class A shares between December 14, 2021 and December 17, 2021, you can file for payment here: https://11th.com/cases/cmlsiii-investor-settlement
$CYCN is a tiny $7M Market Cap Penny Stock with $4.5M Cash that hasn’t diluted at all in the last year and has ZERO DILUTION Filings.
ZERO DEBT.
Trading with a TINY 2M share float.
👇*MUST SEE DD BELOW*👇
This company is ran by VERY high power executives with a very impressive track record.
You won’t find another Biotech penny stock with an $8M valuation that has this kind of leadership.
The new CEO (Regina Graul) appointed in August was the Vice President of $EQRx which got bought out for $950M.
Peter Hecht, PhD - The current director / strategic advisor and EX CEO of $CYCN founded $IRWD (Currently a $654M Company) it was trading over a $3 Billion Dollar Valuation in 2018! (Peter was the CEO of $IRWD from 1998 to 2019)
Another director of $CYCN - Errol De Souza, PhD, founded $NBIX Neurocrine Biosciences Inc (A $12 BILLION DOLLAR COMPANY) trading at $120 per share.
Another director of the company - Michael Higgins served as Interm CEO of $VYGR currently a $368M company.
$EQRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
https://www.chartmill.com/stock/quote/EQRX/fundamental-analysis?key=441b0b4f-77e9-4afc-838b-e3c2de5fc024&utm_source=HEALTH&utm_medium=stocktwits&utm_campaign=FA&utm_content=EQRX
